The total number of shares in Swedish Orphan Biovitrum AB
(publ) (http://www.sobi.com/) (Sobi) as per 31 August 2016 amounts to
272,010,948 shares, whereof 270,389,770 common shares and 1,621,178 class C
shares, corresponding to in total 270,551,887.8 votes. The increase in the
number of shares and votes results from an issue of 188,142 class C shares under
Sobi’s incentive programme. The class C shares are intended to ensure fulfilment
of commitments under incentive programmes. The company holds 1,640,735 common
shares and all 1,621,178 class C shares.
---
About Sobi™
Sobi™ is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on Haemophilia, Inflammation and Genetic diseases. We also market a
portfolio of speciality and rare disease products across Europe, the Middle
East, North Africa and Russia for partner companies. Sobi is a pioneer in
biotechnology with world-class capabilities in protein biochemistry and
biologics manufacturing. In 2015, Sobi had total revenues of SEK 3.2 billion
(USD 385 M) and approximately 700 employees. The share (STO: SOBI) is listed on
Nasdaq Stockholm.
For more information please contact
Media relations Investor relations
Charlotte af Klercker, Sr Jörgen Winroth, Vice
Communications Manager President, Head of Investor
Relations
T: +46-707-297 327 T: +1 347-224-0819, +1 212
-579-0506, +46 8 697 2135
charlotte.afklercker@sobi.com jorgen.winroth@sobi.com
The above information has been made public in accordance with the Swedish
Financial Instruments Trading Act. The information was released for public
distribution on 31 August 2016 at 08:00 CET.
Swedish Orphan Biovitrum AB
Postal address SE-112 76 Stockholm, Sweden
Phone: +46 8 697 20 00 www.sobi.com
New number of shares and votes in Swedish Orphan Biovitrum AB (publ)
| Source: Swedish Orphan Biovitrum AB
Attachments
